Two Different Mechanisms for Weight Loss
Cagrilintide is an amylin analog, a completely different class of drug from retatrutide. Amylin is a hormone secreted alongside insulin by the pancreas that slows gastric emptying and suppresses appetite through separate pathways from GLP-1. Cagrilintide has been studied alone and in combination with semaglutide under the name cagrisema. While cagrilintide’s weight loss is modest alone at 5-10%, the combination with semaglutide produced up to 15.7% weight loss in Phase 2 trials. Retatrutide produces 28.3% weight loss through its triple-agonist mechanism. The choice between them depends on whether you want a single drug that does it all or a novel mechanism from a different drug class.
Clinical Data Comparison
Retatrutide’s Phase 3 TRIUMPH-1 trial showed 28.3% weight loss at 80 weeks on the 12 mg dose. Cagrilintide combined with semaglutide showed 15.7% weight loss in Phase 2 at 32 weeks. No head-to-head trials exist. The gap in efficacy is substantial, but cagrilintide represents a different approach — combining two drugs from different classes — while retatrutide achieves its effects with a single molecule. For researchers and individuals comparing the two, efficacy alone favors retatrutide, but the safety profiles of both compounds are still being established.
Stacking Potential
One of the most discussed combinations in the peptide community is retatrutide and cagrilintide together. The theory is that the two drugs work through completely different receptor systems — GIP/GLP-1/glucagon for retatrutide and amylin for cagrilintide — so their effects may be additive. No clinical data exists on this combination. Theoretically, adding cagrilintide to retatrutide could provide additional appetite suppression through the amylin pathway. Users on Reddit have reported experimenting with this stack, but their experiences are anecdotal and not supported by published research.
Leave a Reply